Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Inks Peptide Delivery Tech Deal with Shire

Premium

Arrowhead Research and Shire this week announced that they have struck an alliance to develop and commercialize drugs combining Arrowhead's targeted delivery peptides and Shire's therapeutic payloads.

Arrowhead acquired the peptide technology in April through its $2.1 million all-stock acquisition of Alvos Therapeutics (GSN 4/12/2012).

Under the deal, Arrowhead will identify peptides that selectively bind and internalize in an undisclosed tissue type, permitting drug delivery.

Arrowhead stands to receive research funding, as well as development, regulatory, and commercialization milestones of up to $32.8 million for each drug candidate, plus royalties. Shire will have the option to exclusively license the candidates and would assume full responsibility for their development and marketing.

Additional terms were not disclosed.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.